Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with ...

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

Glucotrack (GCTK) will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery ...

Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the ...

Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study DataRUTHERFORD, N.J. and STOCKHOLM, April 03, 2025 (GLOBE NEWSWIRE) -- ...

About Glucotrack, Inc. Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently ...

Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on ...

RUTHERFORD, N.J. and STOCKHOLM, April 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel ...